These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Patient who developed heparin-induced thrombocytopenia type II after 24 years on hemodialysis]. Gavranić BB; Basić-Jukić N; Kes P Acta Med Croatica; 2012 Oct; 66 Suppl 2():68-71. PubMed ID: 23513420 [TBL] [Abstract][Full Text] [Related]
3. Clinical evaluation of acute systemic reaction and detection of IgG antibodies against PF4/heparin complexes in hemodialysis patients. Matsuo T; Wanaka K; Miyasita K; Prechel M; Walenga JM Thromb Res; 2012 Apr; 129(4):474-8. PubMed ID: 22088491 [TBL] [Abstract][Full Text] [Related]
4. Heparin-induced thrombocytopenia: an uncommon but serious complication of heparin use in renal replacement therapy. Charif R; Davenport A Hemodial Int; 2006 Jul; 10(3):235-40. PubMed ID: 16805883 [TBL] [Abstract][Full Text] [Related]
5. Immunologic Effects of Heparin Associated With Hemodialysis: Focus on Heparin-Induced Thrombocytopenia. Warkentin TE Semin Nephrol; 2023 Nov; 43(6):151479. PubMed ID: 38195304 [TBL] [Abstract][Full Text] [Related]
6. Risk factors for thrombosis in patients with immune mediated heparin-induced thrombocytopenia. Fabris F; Luzzatto G; Soini B; Ramon R; Scandellari R; Randi ML; Girolami A J Intern Med; 2002 Aug; 252(2):149-54. PubMed ID: 12190890 [TBL] [Abstract][Full Text] [Related]
7. When heparin causes thrombosis: significance, recognition, and management of heparin-induced thrombocytopenia in dialysis patients. Chang JJ; Parikh CR Semin Dial; 2006; 19(4):297-304. PubMed ID: 16893407 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of circuit and AV fistula clotting and detection of anti-PF4/heparin complex antibodies in hemodialysis patients suspected of having heparin-induced thrombocytopenia. Matsuo T; Wanaka K; Walenga JM Clin Appl Thromb Hemost; 2013; 19(1):73-8. PubMed ID: 22345486 [TBL] [Abstract][Full Text] [Related]
9. Heparin-induced thrombocytopenia in hemodialysis patients. Yamamoto S; Koide M; Matsuo M; Suzuki S; Ohtaka M; Saika S; Matsuo T Am J Kidney Dis; 1996 Jul; 28(1):82-5. PubMed ID: 8712226 [TBL] [Abstract][Full Text] [Related]
16. Heparin-induced thrombocytopenia during renal replacement therapy in the intensive care unit. Davenport A Crit Care; 2008; 12(3):158. PubMed ID: 18620549 [TBL] [Abstract][Full Text] [Related]
17. Reducing thrombotic complications in the perioperative setting: an update on heparin-induced thrombocytopenia. Levy JH; Tanaka KA; Hursting MJ Anesth Analg; 2007 Sep; 105(3):570-82. PubMed ID: 17717208 [TBL] [Abstract][Full Text] [Related]
18. Argatroban for heparin-induced thrombocytopenia in hepato-renal failure and CVVHD. Dager WE; White RH Ann Pharmacother; 2003 Sep; 37(9):1232-6. PubMed ID: 12921505 [TBL] [Abstract][Full Text] [Related]
19. Pseudo-pulmonary embolism as a sign of acute heparin-induced thrombocytopenia in hemodialysis patients: safety of resuming heparin after disappearance of HIT antibodies. Hartman V; Malbrain M; Daelemans R; Meersman P; Zachée P Nephron Clin Pract; 2006; 104(4):c143-8. PubMed ID: 16902310 [TBL] [Abstract][Full Text] [Related]
20. Role of platelet factor 4-heparin complex antibody (HIT antibody) in the pathogenesis of thrombotic episodes in patients on hemodialysis. Nakamoto H; Shimada Y; Kanno T; Wanaka K; Matsuo T; Suzuki H Hemodial Int; 2005 Oct; 9 Suppl 1():S2-7. PubMed ID: 16223438 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]